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ABSTRACT
Breast cancer is a leading cause of cancer-related deaths. Anemia is common in 
breast cancer patients and can be treated with blood transfusions or with recombinant 
erythropoietin (EPO) to stimulate red blood cell production. Clinical studies have 
indicated decreased survival in some groups of cancer patients treated with EPO. 
Numerous tumor cells express the EPO receptor (EPOR), posing a risk that EPO 
treatment would enhance tumor growth, but the mechanisms involved in breast tumor 
progression are poorly understood.
Here, we have examined the functional role of the EPO-EPOR axis in pre-
clinical models of breast cancer.  EPO induced the activation of PI3K/AKT and MAPK 
pathways in human breast cancer cell lines. EPOR knockdown abrogated human 
tumor cell growth, induced apoptosis through Bim, reduced invasiveness, and caused 
downregulation of MYC expression. EPO-induced MYC expression is mediated through 
the PI3K/AKT and MAPK pathways, and overexpression of MYC partially rescued loss 
of cell proliferation caused by EPOR downregulation. In a xenotransplantation model, 
designed to simulate recombinant EPO therapy in breast cancer patients, knockdown 
of EPOR markedly reduced tumor growth.
Thus, our experiments in vitro and in vivo demonstrate that functional EPOR 
signaling is essential for the tumor-promoting effects of EPO and underline the 
importance of the EPO-EPOR axis in breast tumor progression.
                      Research Paper
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INTRODUCTION
Breast cancer is a leading cause of cancer-related 
deaths, with 1 in 8 women and 1 in 870 men expected to be 
diagnosed with the disease during their lifetime. Anemia is 
an independent prognostic risk factor in cancer patients [1] 
and is a frequent complication in breast cancer. Although 
recombinant human EPO is an effective treatment for 
anemia, adverse reports of decreased survival in some 
groups of cancer patients in Phase III trials led to a decline 
in its use from 2007 onwards [2] [3]. 
EPO regulates the survival, proliferation and 
differentiation of erythroid progenitor cells through 
activation of its transmembrane receptor, EPOR [4]. 
Besides hematopoiesis, EPO has pleiotropic roles 
in a diverse range of tissues [5, 6]. EPO and EPOR 
expression in neoplasia were first reported in clear cell and 
chromophilic cell renal carcinoma [7] and subsequently 
functional autocrine and paracrine EPO-EPOR systems 
were identified in human breast carcinoma, melanoma, 
prostate cells, and cervical cancer cells [8] suggesting a 
link to tumor progression. Although EPOR expression 
on tumor cells is typically several orders of magnitude 
lower than on erythroid progenitor cells [9], EPO can still 
activate cell signaling cascades in tumor cells, such as in 
differentiated neuroblastoma SH-SY5Y cells, which have 
fewer than 50 EPOR dimers on their cell surface [10]. The 
observation that some cells, such as astrocytes, are capable 
of producing both EPO and EPOR pointed to a functional 
role for EPO as an endocrine, autocrine and paracrine 
factor involving multiple organs [11]. 
Two recent clinical studies implicate EPOR in 
breast tumor growth. In estrogen receptor-positive/
progesterone receptor-positive ER(+)/PR(+) tumors, 
impaired tamoxifen response was correlated with high 
EPOR expression [12]. Tamoxifen treatment significantly 
increased recurrence-free survival in patients with ER(+)/
PR(+) tumors with low EPOR expression but had no 
effect on recurrence-free survival in patients with tumors 
with high EPOR expression. In contrast, recurrence-
free survival was significantly improved in patients with 
ER(+) tumors with high EPOR expression in the untreated 
cohort, implying that EPOR expression in breast cancer 
affects tumor behavior.
In HER2-positive metastatic breast cancer, 
concurrent administration of recombinant EPO and 
trastuzumab correlated with shorter progression-free 
survival and overall survival compared to trastuzumab 
treatment alone [13]. Moreover, exposure of HER2 and 
EPOR dual-positive breast cancer cell lines to trastuzumab 
inhibited AKT and ERK phosphorylation, but the 
inhibition was reduced by simultaneous treatment with 
recombinant EPO. Taken together these reports suggest 
that EPOR expression affects breast tumor progression.
The causative effects of rhEPO and autocrine/
paracrine EPO production on tumor progression are 
poorly understood. Here we have examined the impact 
of EPOR modulation in breast cancer cell lines and in 
a xenotransplantation model designed to simulate EPO 
treatment in cancer patients. A coherent picture has 
emerged, firmly linking the EPO-EPOR axis to breast 
cancer progression.
RESULTS
EPO induces the activation of PI3K/AKT and 
MAPK pathways in human cancer cell lines
In erythroid progenitor cells, EPO binds to EPOR 
and promotes survival, proliferation and differentiation 
through three main signaling pathways JAK2/STAT5, 
PI3K/AKT and MAPK. We investigated the function 
of EPOR in these signaling pathways in MDA-MB-231 
and MDA-MB-435 cells using the clinically relevant 
concentration of 10 U EPO/ml which activated the PI3K/
AKT and MAPK pathways in both cell lines within 10 
minutes, as indicated by increased phospho-AKT (pAKT) 
and phospho-ERK 1/2 (pERK1/2) expression. There were 
no significant changes in the total AKT or total ERK 1/2 
in MDA-MB-231 cells (Figure 1A) or in MDA-MB-435 
cells (Figure 1B). EPO had no effect on the JAK2/STAT5 
pathway in either cell line (data not shown). To investigate 
whether activation of the two pathways is mediated 
specifically by EPOR, we knocked down EPOR expression 
in both cell lines using two independent lentiviral shRNA 
sequences. EPOR expression was suppressed at both 
mRNA (Figure 1C) and protein levels (Figure 1D) by both 
shEPOR#1 and shEPOR#2, compared to the scrambled 
control (shSCR) at 72 hours in MDA-MB-231 cells and in 
MDA-MB-435 cells (data not shown). Addition of EPO 
resulted in lower activation of the PI3K/AKT pathway 
in EPOR-depleted MDA-MB-231 cells as shown by the 
lack of significant increase in pAKT in MDA-MB-231 
cells (Figure 1E). Thus EPO can induce EPOR-dependent 
activation of the AKT signaling pathway in MDA-MB-231 
cells. Addition of EPO to EPOR-depleted MDA-MB-231 
cells did not result in a significant decrease in pERK 
compared to scrambled control cells (data not shown).
EPOR knockdown abrogates human tumor cell 
growth
Using the MTT assay, EPOR-depleted MDA-
MB-231 and MDA-MB-435 cells showed significantly 
reduced viable growth and colony formation compared to 
cells infected with scrambled shRNA (Figure 2A and 2B 
and Supplementary Figure S1A and S1B). These results 
indicate that the EPO-EPOR axis plays an important role 
in sustaining growth in these cell lines.
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EPOR knockdown induces apoptosis through Bim
Since EPO is a survival factor in erythroid 
progenitor cells, we investigated whether EPOR 
knockdown in cancer cell lines would lead to apoptosis. 
EPOR knockdown in both cell lines caused cleavage 
of PARP and caspase 3 (Figure 2C). EPOR knockdown 
increased the expression of BimL and BimS in both cell 
lines (Figure 2D and Supplementary Figure S1C). EPOR 
knockdown had no effect on Bax and Bcl-xL in either cell 
line; Mcl-1 expression was reduced in MDA-MB-231 
cells but was unchanged in MDA-MB435 cells (Figure 
2D and Supplementary Figure S1C). To verify that Bim is 
a mediator of apoptosis induced by EPOR depletion, we 
knocked down Bim by its specific siRNA and found that 
PARP and caspase 3 cleavage were decreased compared to 
cells with EPOR knockdown alone (Figure 2E). Relative 
cell viability in the dual EPOR/Bim knockdown was 
greater than in cells with EPOR knockdown alone after 24 
hours (Figure 2F), suggesting that the survival of tumor 
cells was partially rescued by Bim depletion. The reversal 
of apoptosis caused by siBim was minimal after 48 hours, 
possibly due to degradation of siBim. 
EPO-induced MYC expression is mediated 
through PI3K/AKT and MAPK pathways
We next sought to understand how the EPO/EPOR 
axis exerts these survival and growth effects, particularly 
in the context of breast tumorigenesis. EPO maintains 
c-Myc expression in murine erythroblasts throughout 
their differentiation into reticulocytes [14] and activates 
two distinct pathways required for the initiation and 
elongation of c-Myc in BaF3 immortalized murine pro-B-
cells [15]. In human breast cancer, MYC is amplified and 
overexpressed in 12 to 100% of cases and is associated 
with an aggressive phenotype [16]. To investigate whether 
EPO can increase expression of Myc, the tumor cell 
Figure 1: EPO activates PI3K/AKT and MAPK signaling pathways in breast cancer cells. A. Immunoblot of signaling 
induced by 10 U EPO/ml in MDA-MB-231 cells and B. MDA-MB-435 cells. C. EPOR mRNA expression in MDA-MB-231-shSCR, 
MDA-MB-231-shEPOR#1 and MDA-MB-231-shEPOR#2 cells, generated by infection of pLKO.1-scramble (shSCR), pLKO.1-shEPOR#1 
(shEPOR#1) and pLKO.1-shEPOR#2 (shEPOR#2), harvested 72 hours after lentiviral transduction. Data shown are means ± SEM. shSCR 
vs shEPOR#1, **p = 0.0037; shSCR vs shEPOR#2, *p = 0.0391 by paired t test. D. Immunoblot of EPOR in MDA-MB-231-shSCR, 
MDA-MB-231-shEPOR#1 and MDA-MB-231-shEPOR#2 cells, harvested 72 hours after lentiviral transduction. E. Time course analysis 
of p-AKT and AKT following the addition of 10 U/ml EPO. 
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lines were serum-starved for 24 hours, treated with 10 U 
EPO/ml for 1 hour and the levels of Myc were analyzed. 
Myc protein expression was increased after one hour of 
treatment with EPO in both cell lines (Figure 3A). As 
shown above, EPO activates the expression of PI3K/
AKT and MAPK pathways in tumor cells (Figure 1A, and 
Figure 1B). To determine if EPO-dependent activation 
of MYC is mediated through these pathways, the PI3K 
inhibitor, PI-103 (PI), and the MEK inhibitor, PD184352 
(PD) were tested in the presence or absence of 10 U EPO/
ml. Inhibition of PI3K reversed the increase in pAKT and 
Myc protein expression produced by EPO treatment in 
MDA-MB-231 cells (Figure 3B) and in MDA-MB-435 
cells (Supplementary Figure S2A). MEK inhibition 
reversed the increase in Myc expression produced by 
EPO addition (Figure 3C, Supplementary Figure S2B). 
Therefore, Myc induction caused by EPO is dependent on 
the activation of both the PI3K/AKT and MAPK pathways 
in both cell lines.
EPOR knockdown causes downregulation of 
MYC expression
Next we investigated the effect of shEPOR on the 
endogenous level of Myc without pre-treatment by serum 
starvation or the addition of EPO. Transfection of the cells 
with shEPOR#1 and shEPOR#2 caused a decrease of Myc 
Figure 2: EPOR is essential for growth and prevents apoptosis in breast cancer cells. A. Growth curve of MDA-MB-231 cells 
transduced with shSCR, shEPOR#1, or shEPOR#2 measured by MTT colorimetric assay to determine cell viability. shSCR vs shEPOR#1, 
***p = 0.0003 at Day 3. shSCR vs shEPOR#2, ***p < 0.0001 at Day 3. B. Clonogenic assay of MDA-MB-231-shSCR, MDA-MB-231-
shEPOR#1 and MDA-MB-231-shEPOR#2 cells. Colony number was quantified in three independent replicates after 5 days. shSCR vs 
shEPOR#1, **p = 0.002; shSCR vs shEPOR#2, **p = 0.0041. C. Immunoblots of PARP and Caspase 3 in MDA-MB-231-shSCR, MDA-
MB-231-shEPOR#1 and MDA-MB-231-shEPOR#2 cells, and MDA-MB-435-shSCR, MDA-MB-435-shEPOR#1 and MDA-MB-435-
shEPOR#2 cells harvested 72 hours after transduction. D. Immunoblots of apoptosis-related genes in MDA-MB-231-shSCR, MDA-MB-
231-shEPOR#1 and MDA-MB-231-shEPOR#2 cells, harvested 72 hours after transduction. E. Immunoblots of cleaved forms of PARP 
and Caspase 3 in MDA-MB-231-shSCR, MDA-MB-231-shEPOR#1 and MDA-MB-231-shEPOR#1/siBim dual knockdown cells. Cell 
lysates were prepared 72 hours after knockdown. F. MTT activity of MDA-MB-231-shSCR, MDA-MB-231-shEPOR#1 and MDA-MB-
231-shEPOR#1/siBim dual knockdown cells. Relative cell numbers were determined by MTT assay at both 24 and 48 hours. shEPOR#1 
vs shEPOR#1/siBim at 24 hours, *p = 0.0121. 
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protein expression by 48 hours in both MDA-MB-231 
(Figure 3D) and MDA-MB-435 cell lines (Supplementary 
Figure S2C). Thus EPO can induce Myc expression, 
whereas knockdown of EPOR reduces Myc expression 
independently of EPO.
Knockdown of EPOR reduced Myc protein 
expression in both the cytosolic and nuclear fractions 
in MDA-MB-231 cells (Supplementary Figure S2D), 
and in the nuclear fraction in MDA-MB-435 cells 
(Supplementary Figure S2E). This was confirmed by 
immunofluorescence which showed that Myc is located 
predominantly in the nucleus of both cell lines and that 
Myc expression is reduced in the nucleus of EPOR 
knockdown cells compared to the scrambled control 
(Figure 3E).
Overexpression of MYC partially rescues loss of 
cell proliferation caused by EPOR downregulation
To further delineate the role of MYC regulation 
by EPOR, MYC was transiently transfected into MDA-
Figure 3: EPO induces Myc expression through PI3K/AKT and MAPK pathways and EPOR silencing decreases 
Myc in breast cancer cells. A. Immunoblots of Myc after treatment with 10 U EPO/ml for 1 hour in MDA-MB-231 cells, and in 
MDA-MB-435 cells. B. Immunoblots of Myc, phospho-AKT, AKT, and actin in MDA-MB-231 cells after treatment with 10 U EPO/ml 
for 72 hours, and with addition of the PI3 kinase pathway inhibitor PI-103 (PI) or vehicle (DMSO) at 24 hours. C. Immunoblots of Myc, 
phospho-ERK1/2, ERK1/2, and actin in MDA-MB-231 cells after treatment with 10 U EPO/ml for 72 hours, and with addition of the Ras/
MEK/ERK pathway inhibitor PD184352 (PD) or vehicle (DMSO) at 24 hours. D. Immunoblots of Myc in MDA-MB-231-shSCR, MDA-
MB-231-shEPOR#1 and MDA-MB-231-shEPOR#2 cells, 72 hours following transduction. E. Immunofluorescence analysis of Myc in 
MDA-MB-231-shSCR, MDA-MB-231-shEPOR#2, MDA-MB-435-shSCR and MDA-MB-435-shEPOR#2 cells. Myc was detected using 
anti-Myc primary antibody and Alexa Fluor® 488 secondary antibody, and the nuclei were stained with DAPI (blue). Cells were fixed 72 
hours after transduction. F. Representative growth curves of shSCR pcDNA3.1-control (shSCR-control), shSCR pcDNA3.1-Myc (shSCR-
Myc), shEPOR pcDNA3.1-control (shEPOR-control) and shEPOR pcDNA3.1-Myc (shEPOR-Myc) MDA-MB-231 cells by MTT assay. 
shEPOR-control vs shEPOR-Myc, **p < 0.01. G. Clonogenic assay of shSCR-control, shSCR-Myc, shEPOR-control and shEPOR-Myc 
MDA-MB-231 cells assessed by colony count after 5 days. Images are representative of three independent experiments. H. Quantification 
of colonies in shSCR-control, shSCR-Myc, shEPOR-control and shEPOR-Myc MDA-MB-231 cells. Data are representative of three 
independent experiments. Viable colonies were identified as those with > 50 cells. shEPOR-control vs shEPOR-Myc, ***p = 0.0003.
Oncotarget38256www.impactjournals.com/oncotarget
MB-231 cells followed by lentiviral-mediated EPOR 
knockdown by its specific shRNA (Supplementary 
Figure S2F). After 3 days, the number of EPOR-depleted 
cells with overexpressed MYC (shEPOR-MYC) was 
significantly higher compared to EPOR knockdown alone 
(shEPOR-control) (Figure 3F). MYC overexpression 
enhanced colony formation and partially rescued them 
from the attenuated growth caused by EPOR knockdown 
(Figure 3G and 3H). 
EPOR knockdown reduces invasiveness in human 
tumor cell lines
We next investigated if EPOR regulates migration 
and invasion in tumor cell lines. EPOR knockdown 
caused a 20-60% decrease in cell migration (Figure 4A 
and Supplementary Figure S3A) and a 30-60% decrease 
in cell invasion (Figure 4B and Supplementary Figure 
S3B) in the cell lines. Knockdown of EPOR caused a 
decrease in β-catenin and Snail protein expression in 
both cell lines (Figure 4C and Supplementary Figure 
S3C), but there was no change in Twist expression 
(data not shown). Following fractionation into cytosolic 
and nuclear fractions, β-catenin reduction was more 
pronounced in the cytoplasmic fraction (Supplementary 
Figure 3D and 3E). We extended this analysis to a range 
of epithelial-mesenchymal transition (EMT) markers. 
After EPOR knockdown Slug and fibronectin expression 
was decreased in both cell lines, and E-cadherin protein 
expression increased in both cell lines (Figure 4D and 4E). 
N-cadherin expression decreased in MDA-MB-435 cells 
Figure 4: Effect of EPOR knockdown on migration, invasion and EMT protein expression. A. In vitro migration in MDA-
MB-231-shSCR, MDA-MB-231-shEPOR#1 and MDA-MB-231-shEPOR#2 breast tumor cells, measured as the relative migration through 
membrane inserts with 8 µm pore size, after 24 hours. Data shown are mean fold changes ± SEM for three independent replicates, *p < 0.05, 
paired t test. B. In vitro invasion in MDA-MB-231-shSCR, MDA-MB-231-shEPOR#1 and MDA-MB-231-shEPOR#2 cells, measured 
as the relative invasion through Matrigel-coated invasion chamber inserts with 8 µm pore size. Cells seeded in the upper chamber were 
allowed to migrate through a Matrigel-coated membrane for 24 hours using fetal bovine serum as chemoattractant. Data shown are mean 
fold changes ± SEM for three independent replicates, **p < 0.01, paired t test. C. Immunoblot of β-catenin and Snail in MDA-MB-231-
shSCR, MDA-MB-231-shEPOR#1 and MDA-MB-231-shEPOR#2 cells. Total protein was harvested 72 hours after viral transduction. 
(D,E) Immunoblots of Slug, E-cadherin, N-cadherin, Vimentin and Fibronectin in D. MDA-MB-231-shSCR and MDA-MB-231-shEPOR#1 
cells and in E. MDA-MB-435-shSCR and MDA-MB-435-shEPOR#1 cells. Total protein was harvested 72 hours after viral transduction. 
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but was not detected in MDA-MB-231 cells. There was no 
change in vimentin expression. These results suggest that 
EPOR is required for cancer cell migration and invasion, 
and regulates the expression of proteins that are essential 
for EMT.
Knockdown of EPOR reduces tumor growth in 
vivo
To investigate the role of EPOR in tumor 
development in vivo, MDA-MB-231-D3H2 cells 
harboring either a tet-on-inducible shEPOR (shEPOR) or 
a tet-on-inducible scrambled shSCR sequence (shSCR) 
were prepared and validated prior to subcutaneous (s.c.) 
injection in B6N nude female mice (Supplementary Figure 
S4A, S4B, S4C and S4D).
To simulate treatment of anemia in cancer patients, 
all mice were treated with recombinant human EPO (500 
U/kg) by intra-peritoneal injection twice per week. Tumor 
growth in the shEPOR+dox subgroup was significantly 
reduced compared to the shSCR-dox, shSCR+dox and 
shEPOR-dox subgroups (Figure 5A). Doxycycline-induced 
knockdown of EPOR significantly increased tumor tripling 
time from 12.0±1.6 (shSCR-dox), 11.2±1.5 (shSCR+dox), 
12.0±1.0 (shEPOR-dox) days to 23.6±2.6 (Figure 5B). IVIS 
imaging of time-matched shEPOR-dox and shEPOR+dox 
mice at Day 15 indicated a reduction in bioluminescence 
activity in the shEPOR+dox mice (Figure 5C). Mice in the 
shEPOR+dox subgroup had a significantly increased mean 
survival time to maximum tumor limit (30 days) compared 
to the other three subgroups (mean of 14.7 days) (Figure 
5D).
Analysis of tumor material from each of the 
four subgroups by RNAscope®, using human EPOR 
probes, showed substantially lower expression of 
EPOR in the shEPOR+dox subgroup compared to the 
other three subgroups (Figure 5E). Furthermore, 
Figure 5: Effect of EPOR knockdown on breast tumor growth in vivo. A. Tumor volume measurements of mice in the four 
subgroups, shSCR-dox (n = 7), shSCR+dox (n = 7), shEPOR-dox (n = 7) and shEPOR+dox (n = 6), following the commencement of doxycycline 
and EPO treatment at 100 mm3 tumor volume. B. Tumor tripling time in days for the tumor to grow from 100 mm3 to 300 mm3. ***p < 
0.0001 for shEPOR+dox vs shSCR-dox ; shEPOR+dox vs shSCR+dox ; shEPOR+dox vs shEPOR-dox ; and shEPOR+dox vs shEPOR-dox, Bonferroni’s 
Multiple Comparison Test. All other comparisons between subgroups were non-significant (NS). C. In Vivo Imaging System (IVIS) time-
matched images of one shEPOR-dox mouse (left lane) and three shEPOR+dox mice on Day 15. D. Kaplan-Meier plot of the survival time 
in shSCR-dox, shSCR+dox, shEPOR-dox and shEPOR+dox animals. Mice were culled when the tumor volume reached 400 mm3; *p = 0.0127, 
log-rank (Mantel-Cox) test. E. RNAscope® analysis of EPOR expression in representative tumors from shSCR-dox, shSCR+dox, shEPOR-dox 
and shEPOR+dox mice. Scale bar represents 10 µm. F. Immunohistochemical analysis of EPOR expression, using the anti-EPOR antibody 
GM1201, in representative tumors from shSCR-dox, shSCR+dox, shEPOR-dox and shEPOR+dox mice. Images were taken at x40 magnification. 
Scale bar represents 10 µm.
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immunohistochemical staining also confirmed reduced 
EPOR expression in tumors from shEPOR+dox mice (Figure 
5F). 
The tumor-bearing mice showed small increases 
in red cell count, hemoglobin, and hematocrit, indicating 
that they had not become anemic over the experimental 
period (Supplementary Figure S4E). Imaging of turbo 
Red Fluorescence Protein (tRFP) showed consistent tRFP 
fluorescence in shEPOR+dox mice whereas no tRFP signal 
was detected in shEPOR-dox mice, (Supplementary Figure 
S4F), indicating that the dox-inducible shEPOR vector 
was functionally active in vivo for up to 7 weeks post 
transplantation. 
DISCUSSION
The JAK2/STAT5, PI3K/AKT and MEK/ERK 
signaling pathways are frequently altered in tumor cells 
and evidence that EPO induces these signal transduction 
cascades is accumulating [17-19]. Previously we showed 
that EPO-induced activation of the JAK2/STAT5, PI3K/
AKT and Ras/ERK pathways promotes malignant cell 
behavior in a benign non-invasive rat cell line Rama 37 
stably transfected with human EPOR [9]. Here we have 
investigated the effects of EPOR knockdown in two human 
breast cancer cell lines and in a xenotransplantation model 
designed to mimic EPO therapy in breast cancer patients. 
Given that EPO-induced signalling components are more 
readily detected in the Rama 37 cells overexpressing 
EPOR, the results of the two studies are in good agreement 
and corroborate the idea that the EPO-EPOR axis is 
important in breast cancer progression. 
Knockdown of EPOR caused an increase in 
apoptotic activity in both MDA-MB-231 and MDA-
MB-435 cell lines, as demonstrated by increased cleavage 
of PARP and caspase 3. Moreover EPOR knockdown 
caused an increase in the expression of BimL and BimS, 
which are BH3-only proteins of the Bcl-2 family that 
regulate the cell death program via the mitochondrial 
apoptotic pathway. Bim binds to pro-survival proteins 
such as Mcl-1 and releases Bax to initiate cell death [20, 
21]. This may explain our observation that the level of 
Bax protein expression was not changed upon silencing 
of EPOR, in spite of the increase in apoptosis. Bim is also 
regulated in part by post-translational modification [22]. 
In particular ERK1/2 phosphorylates BimEL causing rapid 
degradation via the proteasome pathway, whereas ERK1/2 
does not contribute to the degradation of BimS or BimL 
[22]. EPOR silencing causes impairment of the MAPK 
pathway leading to increased stability of Bim. In cells with 
combined EPOR and Bim downregulation, apoptosis was 
decreased compared to cells with EPOR downregulation 
alone. This confirms that Bim is involved in apoptosis and 
that EPOR-mediated signaling contributes to survival in 
both cell lines. However the apoptotic effect after EPOR 
knockdown was not completely reversed suggesting that 
other mediators of apoptosis are involved. 
The PI3K pathway mediates many cellular processes 
including proliferation, differentiation, ribosomal 
biosynthesis and mitochondrial function, and is frequently 
dysregulated in cancer. c-Myc is highly expressed in 
many human cancers and is associated with poor clinical 
outcome [23]. EPO increases MYC expression in erythroid 
progenitor cells [14] and we found that EPO increases 
Figure 6: Effects of knockdown of EPOR in breast cancer cell lines. Schematic diagram illustrating effects of EPOR depletion 
on downstream signaling proteins and on breast cancer cell growth, apoptosis, invasion and migration.
Oncotarget38259www.impactjournals.com/oncotarget
MYC expression in both breast cancer cell lines. Moreover 
AKT, a canonical downstream effector of PI3K, and 
MAPK can affect transcription and degradation of Myc 
[24] so we questioned whether activation of the PI3K/
AKT and MAPK pathways and the increase in Myc are 
causally linked. PI103, a potent inhibitor of PI3K, and 
PD184352, a specific inhibitor of MEK, were each able 
to block the increase in Myc expression, indicating that 
both pathways are involved in the EPO-induced increase 
in Myc found in both cell lines.
EPO has been reported to increase lymph node 
lymphangiogenesis and lymph node tumor metastasis in 
a mouse model of breast cancer [25]. These effects were 
associated with increased migration, capillary-like tube 
formation, and dose- and time-dependent proliferation 
of human lymphatic endothelial cells. Interestingly these 
effects were abrogated by co-treatment with specific 
inhibitors of PI3K or MAPK, under conditions in which 
EPO increased AKT and ERK1/2 phosphorylation and are 
consistent with our current data.
Lentiviral-mediated silencing of EPOR inhibited 
activation of the PI3K/AKT and MAPK pathways, leading 
to downregulation of MYC and reduced cell proliferation. 
Overexpression of MYC partially rescued the decrease 
in proliferation caused by EPOR silencing, indicating an 
overlap in the pathways downstream of EPOR signaling 
and Myc activation, and that Myc is important in EPOR-
mediated cell survival. If this observation in vitro holds in 
vivo it would imply that EPO-induced signaling interacts 
with Myc, which is frequently amplified and over-
expressed in breast tumors [16].
The epithelial-mesenchymal transition (EMT) is 
widely held to be critical for tumor invasiveness. In this 
process epithelial cells undergo multiple biochemical 
changes to develop a mesenchymal phenotype, which 
generally exhibits enhanced migratory capacity, 
invasiveness, elevated resistance to apoptosis, and 
increased production of extracellular matrix components 
[26] Here, we showed that EPOR knockdown caused 
both tumor cell lines to become more epithelial-like. 
The endogenous levels of E-cadherin, a transmembrane 
protein that controls homophilic cell-cell adhesion and 
maintains cells in an epithelial phenotype [27] were low, 
but increased after EPOR knockdown, accompanied by a 
decrease in N-cadherin. No N-cadherin expression could 
be detected in the MDA-MB-231 cells, consistent with 
previous data [28].
E-cadherin and N-cadherin appear to have a 
reciprocal relationship. N-cadherin is expressed primarily 
in tissues of mesenchymal origin, and upregulation of 
N-cadherin enhances cell invasiveness and mobility [29]. 
Switching from E-cadherin to N-cadherin promotes tumor 
progression and correlates with multiple clinical outcomes 
[30] [31]. The increase in E-cadherin may also be caused 
by the decrease in Snail, a transcriptional repressor of 
E-cadherin. After EPOR knockdown β-catenin was 
decreased in the nuclear fraction, reducing its binding 
to transcription factors of the T-cell factor (TCF) family 
and its capacity to modulate the downstream target genes 
involved in EMT [30]. 
The effects of EPOR knockdown on both cell lines 
are summarized in Figure 6. After EPOR knockdown Myc 
is decreased, and is associated with decreased cell growth, 
increased apoptosis, and changes in EMT-related proteins 
linked to decreases in invasive and migratory capacity.
To investigate the role of EPOR in breast tumor 
progression we used a murine xenotransplantation model 
which simulated EPO therapy in cancer patients. Tumor 
growth in the MDA-MB-231-D3H2-shEPOR subgroup 
treated with doxycycline (shSCR+dox) was dramatically 
reduced and showed substantially lower expression of 
EPOR by in situ hybridization than the control subgroups, 
indicating that EPO-EPOR axis is active in breast tumor 
progression in this model. 
Cell type-specific differences in EPOR signalling 
between primary erythroid and H838 lung cancer cells 
have recently been defined using a systems biology 
approach [32]. Seven cell type-specific parameters 
including nuclear location, translocation of STAT5 and 
target gene induction were identified. The model also 
predicted that JAK2 inhibition in combination with EPO 
treatment would selectively inhibit H838 cells compared 
to erythroid cells. This prediction is of particular interest 
because the JAK2 inhibitor Fedratinib was found to be 
synergistic with chemotherapy for breast tumor-initiating 
cells in autochthonous genetically engineered murine 
models [24]. Furthermore the efficacy of the JAK2 
inhibitor Ruxolitinib is currently being investigated in 
combination with cisplatin in clinical trials in non-small 
cell lung carcinoma (NSCLC) [33]. 
MATERIALS AND METHODS
Cell lines
Human cancer cell lines MDA-MB-231 and 
MDA-MB-435 and the viral packaging cell line 293T 
were obtained from American Type Culture Collection 
(Manassas, VA). Both cancer cell lines are characterised 
by the lack of expression of ERα, PR and HER2 i.e. they 
are classified as triple negative. The origin of MDA-
MB-435 is controversial, having been classified both as a 
breast cancer and as a melanoma cell line [34].
Cell culture
Cell lines were maintained in Dulbecco’s 
modified Eagle medium (DMEM) with high glucose 
and L-glutamine (PAA Laboratories) supplemented with 
10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/
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ml streptomycin. The cells were routinely cultured in a 
humidified incubator at 37°C supplemented with 5% CO2. 
Before stimulation with EPO, cells were serum-starved for 
24 hours. 
Recombinant DNA constructs
Plasmids
pLKO.1-shEPOR#1 and pLKO.1-shEPOR#2 (clone 
IDs NM_000121.2-539s1c1 and NM_000121.2-1399s1c1 
respectively) were purchased from Sigma. pLKO.1-
scramble (SCR, #1864) and pcDNA3-cMyc (#16011) 
were from Addgene, and siBim (clone ID SI02655359) 
was from Qiagen. Scramble siRNA sequences: sense 
5′-UUGUACGGCAUCAGCGUUAdTdT-3′; and 
antisense 5′-UUACGCUGAUGCCGUACAAdTdT-3′ 
were from Amaxa GmbH.
Transfection and viral infection
Genejuice® (Novagen) was used for transfection of 
expression plasmids or shRNA. For generation of cell lines 
with EPOR knockdown, 293T cells were first transfected 
with shRNA. Viral particle-containing medium was 
harvested 48 hours after transfection and used to transduce 
target breast cancer cells supplemented with 6 µg/ml 
polybrene. Four hours after infection, cells were refreshed 
with complete medium and a further cycle of infection 
was performed 24 hours later. Equivalent amounts of 
viral particles from the same batch of medium were used 
to achieve similar knockdowns to enable comparison 
of different treatments within a given experiment. For 
siRNA transfection, siPORT NeoFX transfection agent 
(Ambion, Life Technologies) was used according to the 
manufacturer’s instructions.
Quantitative RT-PCR
Total RNA was extracted using TRIzol (Invitrogen). 
The first-strand cDNA was synthesized from 1 μg RNA 
using the GeneAmp RNA PCR kit (Applied Biosystems). 
TaqMan probes were used for quantitative RT-PCR: EPOR 
(Hs00181092_1), 18S (4319413E) and analyzed using the 
ABI 7500H Light Cycler (Applied Biosystems).
Inhibitors
PD184352 (a gift from Dr James Murray) and PI103 
(Merck) were reconstituted in DMSO. 
Western blot
Cells were lysed in RIPA buffer [50 mM Tris-HCl 
(pH 8.0), 150 mM NaCl, 1% (v/v) NP-40, 0.5% (w/v) 
deoxycholate, and 0.1% (w/v) SDS, supplemented with 
phenylmethylsulfonyl fluoride, sodium orthovanadate, and 
a cocktail of protease inhibitors. The N-Per kit (Thermo 
Fisher Scientific) was used for cellular fractionation. 
Protein concentrations of the cell lysates were measured 
by the DCTM Protein assay (Bio-Rad Laboratories). 
Sources of antibodies used in western blots
Mouse monoclonal antibodies against tubulin and 
actin were from Sigma and anti-phospho-ERK from 
Cell Signaling Technology. Polyclonal antibodies for the 
EMT markers, Bcl-2 family members, PARP, cleaved 
caspase 3, ERK, phospho-ERK, AKT, phospho-AKT 
(Serine 473), were from Cell Signaling Technology. Anti-
TATA binding protein (TBP) antibody was from Abcam. 
Antibodies for Myc and EPOR (C20) were from Santa 
Cruz Biotechnology. For immunohistochemistry, the 
EPOR antibody GM1201 was used (Aldevron GmbH).
Fluorescence microscopy
Cells grown on coverslips were fixed with ice-cold 
methanol and staining performed as described previously 
[35]. Myc was visualised using an anti-Myc primary 
antibody and Alexa Fluor® 488 secondary antibody, and 
the nucleus counterstained with DAPI. The cell staining 
was visualized using an Eclipse Ti-S microscope (Nikon).
Quantitative RT-PCR
Total RNA was extracted using TRIzol (Invitrogen). 
The first-strand cDNA was synthesized from 1 μg RNA 
using the GeneAmp RNA PCR kit (Applied Biosystems). 
TaqMan probes were used for quantitative RT-PCR: EPOR 
(Hs00181092_1), 18S (4319413E) and analyzed using the 
ABI 7500H Light Cycler (Applied Biosystems).
Invasion and migration assays
Invasion was measured using Matrigel-coated multi-
well inserts as previously described [9]. Matrigel-coated 
invasion chambers (6.4-mm diameter: 8-µm pore size; BD 
Biosciences) were used to assess the invasive capacity of 
MDA-MB-231-shSCR, MDA-MB-231-shEPOR#1 and 
MDA-MB-231-shEPOR#2 breast tumor cells. Briefly, 1 
x 105 cells were resuspended in serum-free, phenol-red 
free media and placed in the upper chambers. The cultures 
were incubated for 18 hours at 37ºC in a 5% (v/v) CO2 
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atmosphere. The upper surfaces of the filters were wiped 
clean of cells and the filters were fixed by immersion in 
100% (v/v) methanol and stained in 0.5% crystal violet 
for 25 minutes. Each membrane was washed in running 
distilled water and left to air-dry. After washing with 
sodium citrate/ethanol for 30 minutes, 200 µL of the 
solution were transferred into a 96-well plate and read at 
570 nm in a Tecan plate reader. The percentage of invasion 
of each cell type was normalized using the percentage of 
invasion of MDA-MB-231-shSCR as 100%.
The migration assay was similar to the invasion 
assay except that the insert membrane was not coated with 
Matrigel. The percentage of migration of each cell type 
was normalized using the percentage of invasion of MDA-
MB-231-shSCR as 100%.
Viability and clonogenic assays
To assess cell viability, MTT assays were performed. 
Briefly, 4 x 103 cells per well were seeded in a 96-well 
plate after infection, and allowed to grow until the time 
points shown prior to the replacement with 100 µL 
fresh medium containing 10 µL of 5 mg/mL MTT. After 
incubation for 3 hours the crystallized MTT precipitates 
in each well were dissolved in DMSO and the absorbance 
was measured at 570 nm.
Cell clonogenicity was measured by seeding cells 
in 6-well plates. 
Xenotransplantation model
The role of EPOR in tumor development was 
investigated in a xenotransplantation model using 
immunocompromised female B6.Cg/N-Foxn1nu/nu nude 
mice. Mice were s.c. injected with either control MDA-
MB-231-D3H2-shSCR (shSCR) or MDA-MB-231-D3H2-
shEPOR (shEPOR) cells. When the tumor volume reached 
100 mm3 all mice were injected intraperitoneally twice 
weekly with EPO and EPOR-knockdown was initiated by 
ad libitum consumption of drinking water containing 1 μg/
ml doxycycline and 50 mg/ml sucrose.
Immunohistochemistry
Tumor samples were fixed in formal saline (Premier 
Scientific) for 24 hours and processed to paraffin wax. 
Serial sections were cut at 4 µm, air-dried overnight and 
dewaxed. Antigen retrieval was performed by pressure-
cooking for 2 minutes in TE buffer pH 9.0 and samples 
stained using the GM1201 anti-EPOR antibody at 4 µg/ml 
overnight at 4ºC. Localisation was performed using rabbit 
anti-rat IgG (Thermo Fisher Scientific) at 10 µg/ml for 
30 minutes at ambient temperature and Rabbit Envision/
Diaminobenzidine (Dako). Sections were counterstained 
in Meyer’s hematoxylin. 
In Situ hybridization
Serial sections from tumors were stained for EPOR 
mRNA using chromogenic RNAscope® (Advanced Cell 
Diagnostics). After being air-dried overnight, sections 
were baked at 60ºC for 1 hour, de-waxed and air-dried 
before pre-treatments. For all probes the sections were 
subjected to a mild pre-treatment protocol and RNAscope® 
probes Hs-EPOR and a positive control probe. Detection 
of specific probe binding sites was performed with 
RNAscope® 2.0 HD Reagent kit. All sections were 
counterstained in Meyer’s hematoxylin.
All experiments were performed in at least three 
independent experiments. The statistical tests used in 
each graph are described in the Figure legends. In all 
experiments, statistical significance was indicated as: p < 
0.05 *; p < 0.01 **; p < 0.001 ***. 
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